Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
ASMB 
Assembly Biosciences Inc (ASMB)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
02/03/2025: ASMB (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
2 Analysts rated it
These Stocks/ETFs, based on Upturn Advisory, have historically outperformed the market, making them a top-tier choice for investors.
Year Target Price $30
Year Target Price $30
| 2 | Strong Buy |
| 0 | Buy |
| 0 | Hold |
| 0 | Under performing |
| 0 | Sell |
Analysis of Past Performance
Type Stock | Historic Profit -46.62% | Avg. Invested days 29 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 02/03/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 132.21M USD | Price to earnings Ratio - | 1Y Target Price 30 |
Price to earnings Ratio - | 1Y Target Price 30 | ||
Volume (30-day avg) - | Beta 0.55 | 52 Weeks Range 7.75 - 19.93 | Updated Date 06/29/2025 |
52 Weeks Range 7.75 - 19.93 | Updated Date 06/29/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -6.2 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -124.15% | Operating Margin (TTM) -105.54% |
Management Effectiveness
Return on Assets (TTM) -25.49% | Return on Equity (TTM) -133.65% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 44198042 | Price to Sales(TTM) 4.11 |
Enterprise Value 44198042 | Price to Sales(TTM) 4.11 | ||
Enterprise Value to Revenue 1.37 | Enterprise Value to EBITDA 0.42 | Shares Outstanding 7637550 | Shares Floating 4637980 |
Shares Outstanding 7637550 | Shares Floating 4637980 | ||
Percent Insiders 39.25 | Percent Institutions 12.77 |
Analyst Ratings
Rating 5 | Target Price 30 | Buy - | Strong Buy 2 |
Buy - | Strong Buy 2 | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Assembly Biosciences Inc
Company Overview
History and Background
Assembly Biosciences, Inc. was founded in 2005. It is a biotechnology company focused on developing novel therapeutics targeting hepatitis B virus (HBV) infection. The company has evolved through various phases of research and clinical development, focusing on core inhibitor and viral entry inhibitor programs.
Core Business Areas
- HBV Program: Assembly Biosciences focuses on developing and commercializing direct acting antiviral therapeutics for the treatment of HBV infection. This includes developing core inhibitors and other potential HBV therapies.
Leadership and Structure
The leadership team consists of the CEO, CFO, Chief Medical Officer, and other key executives. The organizational structure is typical of a biotechnology company, with departments focused on research, clinical development, regulatory affairs, and commercial operations.
Top Products and Market Share
Key Offerings
- Vebicorvir (ABI-H0731): Vebicorvir is a core inhibitor being developed for the treatment of chronic HBV infection. Its market potential depends on its clinical success and eventual approval. Competitors include other HBV therapeutics from companies like Gilead Sciences and Roche.
- ABI-4334: An oral HBV surface antigen (HBsAg) secretion inhibitor. Competitors include other HBV therapeutics from companies like Gilead Sciences and Roche.
Market Dynamics
Industry Overview
The industry is characterized by a significant unmet need for effective HBV therapies, driving intense competition and innovation. The Hepatitis B market consists of nucleos(t)ide analogues and interferon injections. Development of curative therapy is a major focus.
Positioning
Assembly Biosciences is positioned as a company focused on developing novel core inhibitors for HBV, aiming to achieve functional cures. Their competitive advantage lies in the potential efficacy and safety profile of their core inhibitors and HBsAg inhibitors.
Total Addressable Market (TAM)
The global market for Hepatitis B therapeutics is estimated to be several billion dollars. Assembly Biosciences is positioned to capture a portion of this TAM with successful development and commercialization of their pipeline assets. Exact TAM figures vary depending on the source but are in the $3-5 billion range globally.
Upturn SWOT Analysis
Strengths
- Novel Core Inhibitor Technology
- Experienced Management Team
- Targeting a Large Unmet Medical Need
- Strong Intellectual Property Portfolio
Weaknesses
- Reliance on Pipeline Success
- Limited Commercial Infrastructure
- Competition from Established Players
- High R&D Expenditure
Opportunities
- Partnerships with Larger Pharmaceutical Companies
- Expansion into Other Viral Diseases
- Advancements in HBV Diagnostics
- Favorable Regulatory Environment
Threats
- Clinical Trial Failures
- Regulatory Hurdles
- Competition from Novel Therapies
- Pricing Pressures
Competitors and Market Share
Key Competitors
- GILD
- ROCHE.SW
- ABUS
Competitive Landscape
Assembly Biosciences faces competition from established pharmaceutical companies with approved HBV therapies. Assembly Biosciences' advantage comes from a potential for curative therapies and has novel technology
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been largely driven by clinical trial progress and partnerships.
Future Projections: Future growth projections are contingent on clinical trial outcomes, regulatory approvals, and commercial success.
Recent Initiatives: Recent initiatives include advancing clinical trials of core inhibitors and HBsAg inhibitors, and forming partnerships to expand development efforts.
Summary
Assembly Biosciences is a biotechnology company focusing on HBV therapies with innovative approaches. Its success heavily relies on the clinical trial outcomes of its core inhibitor and HBsAg inhibitor programs. While facing competition from established giants, the companyu2019s novel technology offers potential advantages. Monitoring trial results and securing partnerships are crucial for their future success.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Industry Reports
- Analyst Reports
Disclaimers:
The information provided is for informational purposes only and should not be considered financial advice. Investment decisions should be made based on individual due diligence.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Assembly Biosciences Inc
Exchange NASDAQ | Headquaters South San Francisco, CA, United States | ||
IPO Launch date 2010-12-17 | CEO, President & Director Mr. Jason A. Okazaki J.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 73 | Website https://www.assemblybio.com |
Full time employees 73 | Website https://www.assemblybio.com | ||
Assembly Biosciences, Inc., a biotechnology company, develops therapeutic candidates for the treatment of viral diseases worldwide. Its pipeline includes long-acting helicase-primase inhibitors candidates, including ABI-5336 and ABI-1179, which are in Phase 1a/1b clinical studies for recurrent genital herpes; ABI-4334, a capsid assembly modulator designed to disrupt the replication cycle of hepatitis B virus that is in Phase 1b clinical study; and ABI-6250, an orally bioavailable hepatitis delta virus entry inhibitor that is in Phase 1a clinical study. The company also develops ABI-7423, an oral broad-spectrum non-nucleoside polymerase inhibitor that targets transplant-related herpesviruses. It has an option, license, and collaboration agreement with Gilead Sciences, Inc. for the research and development of virology therapies. The company was formerly known as Ventrus Biosciences, Inc. and changed its name to Assembly Biosciences, Inc. in June 2014. Assembly Biosciences, Inc. was incorporated in 2005 and is headquartered in South San Francisco, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.